What is the NILO-PD?
The Parkinson Study Group (PSG), under the direction of Tanya Simuni, MD (Northwestern University) is conducting a multi-center, randomized, double-blind, placebo-controlled study of nilotinib in individuals with Parkinson’s disease (PD).
The purpose of the NILO-PD study is to determine if nilotinib is safe, if it can be tolerated by patients with PD and to learn if nilotinib has the possibility of effectively treating PD symptoms. Twenty-five sites will enroll participants into 2 cohorts, approximately 75 in Cohort 1 and 60 in Cohort 2. Cohort 1 will be enrolling first and participants will have moderate to advanced PD. Cohort 2 will enroll after the completion of Cohort 1 and participants will have early PD.
NILO-PD is being conducted under a research grant award from the Michael J. Fox Foundation for Parkinson’s Research.
What is the Inclusion/Exclusion Criteria for the NILO-PD Study?
Participants must meet certain criteria. Some are:
- You must be between the ages of 40 and 79
- You must have been diagnosed with Parkinson’s disease (PD) for more than 5 years
- You need to be on a stable regimen of PD medications that includes levodopa for at least 30 days prior to screening visit
What will I have to do throughout the study?
- Nilotinib is a capsule that will be taken orally on a daily basis.
- The study will include 11 in person study visits.
- Clinical assessments and questionnaires will be completed
- Several blood samples will be collected throughout the study
- Certain visits will require a Lumbar Puncture (LP)
For more information, click here.